The Pipeline
   
  ARMGO is currently working to impact diseases by targeting distinct indications. ARMGO began cardiac phase 1 trials in Europe in May 2008.
   
   
   
   
   
   

Current News


 

Bellinger AM, Reiken S, Carlson C, et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nature Medicine 2009;10.1038/nm.1916   Link to Article

Prof. Andrew Marks presentation on, "Mechanism-Based Therapies for Heart Failure and Cardiac Arrhythmias" from the Henry Stewart Talks, Series, "Calcium Signalling: Regulation, Mechanisms, Effectors, Role in Disease and Recent Advances".
Link to Presentation